Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Vessix Vascular
March 15, 2016
Interview – ReCor hopes to find Paradise on the market
September 03, 2015
Interview – Boston’s long road to recovery
August 26, 2015
Medtronic enters mitral valve race with obscure $400m buy
September 10, 2014
Mesh lawsuits could derail Boston’s big year
May 15, 2014
Purchase of Bayer unit bulks Boston’s peripheral portfolio
May 02, 2014
EP Vantage interview – EdRIP backs Axonics thanks to management team
January 22, 2014
Covidien exits and Boston pauses, but renal denervation has not burned out
October 24, 2013
Job cuts at Boston indicative of an industry in flux
July 01, 2013
Boston gains Bard’s rhythm in $275m deal
June 25, 2013
EP Vantage interview – JenaValve aims to triple sales or sell itself
November 09, 2012
Boston Scientific gatecrashes renal denervation market with Vessix buy
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
August 12, 2022
Q2 Roundup Infographic
August 10, 2022
Q2 Roundup eBook
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
